Supplementary Table S3 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer

Supplementary Table S3 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer

<p>Multivariable Cox proportional hazards models for time to progression and time to death</p>

Saved in:

书目详细资料
主要作者:	Sofie H. Tolmeijer (15313251) (author)
其他作者:	Emmy Boerrigter (15313254) (author), Takayuki Sumiyoshi (15034119) (author), Edmond M. Kwan (15313257) (author), Sarah W.S. Ng (14960841) (author), Matti Annala (15313260) (author), Gráinne Donnellan (15313263) (author), Cameron Herberts (14960820) (author), Guillemette E. Benoist (15313266) (author), Paul Hamberg (15313269) (author), Diederik M. Somford (15035198) (author), Inge M. van Oort (15035171) (author), Jack A. Schalken (15313272) (author), Niven Mehra (15011036) (author), Nielka P. van Erp (15313275) (author), Alexander W. Wyatt (14960922) (author)
出版:	2025
主题:	Cancer Cancer Detection and Diagnosis Methods and Technology Biomarkers Circulating tumor cells/DNA/exosomes Genitourinary Cancers Prostate cancer Liquid Biopsy
标签:	添加标签没有标签, 成为第一个标记此记录!

相似书籍

Supplementary Table S1 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
由: Sofie H. Tolmeijer (15313251)
出版: (2025)

Supplementary Table S2 from Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
由: Sofie H. Tolmeijer (15313251)
出版: (2025)

Supplementary Data 2 from Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study
由: Ismael Fernández-Miranda (15051932)
出版: (2025)

Supplementary Data S1 from Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
由: Andrew A. Davis (15030032)
出版: (2025)

Supplementary Data 1 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis
由: Nam Q. Bui (14958210)
出版: (2025)

TS1-9 from Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer
由: Lavanya Sivapalan (15314248)
出版: (2025)

Supplemental Table 1 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
由: Morten Lapin (15056728)
出版: (2025)

Supplemental Table 2 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
由: Morten Lapin (15056728)
出版: (2025)

Supplemental Table 3 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
由: Morten Lapin (15056728)
出版: (2025)

Supplementary Table S3 from Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma
由: Jun Wang (15051911)
出版: (2025)

Supplementary Data 1 from Early Changes in Circulating Cell-Free <i>KRAS</i> G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients
由: Cloud P. Paweletz (14960112)
出版: (2025)

Supplementary Figure S1 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
由: Javier Pascual (15018176)
出版: (2025)

Supplementary Figure S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
由: Javier Pascual (15018176)
出版: (2025)

Supplementary Figure S3 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
由: Javier Pascual (15018176)
出版: (2025)

Supplementary Figure S4 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
由: Javier Pascual (15018176)
出版: (2025)

Supplementary Figure S5 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
由: Javier Pascual (15018176)
出版: (2025)

Supplementary Table S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
由: Javier Pascual (15018176)
出版: (2025)

Supplementary Table S3 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
由: Javier Pascual (15018176)
出版: (2025)

Supplementary Figure S7 from <i>NPY</i> Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer
由: Katleen Janssens (15053356)
出版: (2025)

Supplementary Table S1 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
由: Stephanie Lheureux (16797697)
出版: (2025)

Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
由: Stephanie Lheureux (16797697)
出版: (2025)

Supplementary Table S3 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
由: Stephanie Lheureux (16797697)
出版: (2025)

Supplementary Table S4 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
由: Stephanie Lheureux (16797697)
出版: (2025)

Supplementary Table S5 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
由: Stephanie Lheureux (16797697)
出版: (2025)

Supplementary Data 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
由: Whitney L. Hensing (16461978)
出版: (2025)

Table S1-S8 from Urinary Tumor DNA MRD Analysis to Identify Responders to Neoadjuvant Immunotherapy in Muscle-invasive Bladder Cancer
由: Ruiyun Zhang (17142498)
出版: (2025)

Table S1 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
由: N. Ari Wijetunga (15056183)
出版: (2025)

Table S2 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
由: N. Ari Wijetunga (15056183)
出版: (2025)

Table S3 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
由: N. Ari Wijetunga (15056183)
出版: (2025)

Table S4 from Dynamic Mutational Landscape of Cerebrospinal Fluid Circulating Tumor DNA and Predictors of Survival after Proton Craniospinal Irradiation for Leptomeningeal Metastases
由: N. Ari Wijetunga (15056183)
出版: (2025)

Supplementary Figure S1 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
由: Kala Visvanathan (14952973)
出版: (2025)

Supplementary Figure S2 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
由: Kala Visvanathan (14952973)
出版: (2025)

Supplementary Figure S3 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
由: Kala Visvanathan (14952973)
出版: (2025)

Supplementary Figure S4 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
由: Kala Visvanathan (14952973)
出版: (2025)

Supplementary Figure S5 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
由: Kala Visvanathan (14952973)
出版: (2025)

Supplementary Tables S1-S15 from Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells
由: Iris van 't Erve (15054503)
出版: (2025)

Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
由: Francesca Orzan (15055579)
出版: (2025)

Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
由: Francesca Orzan (15055579)
出版: (2025)

Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
由: Francesca Orzan (15055579)
出版: (2025)

Figure 1 from The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
由: Martin Sjöström (14845882)
出版: (2025)

Cannot write session to /tmp/vufind_sessions/sess_t1afoalf3v2qtq0lck5bik3ilr